Missed out the webinar? 

Just click to view the videos: 

Cancer-Derived iPSC as Cancer Model: An Overview, by Dr. Erica Choong

iPSC Technology: Their Role in Regenerative Medicine, by Ms. Tai LiHui

Mesenchymal Stem Cells: Application in Cell and Gene Therapy, by Dr. Teoh Hoon Koon 

Q & A session with the speakers and the Dean of UTAR Faculty of Medicine & Health Sciences:

Prof. Chua Chee Wai

(1) Prof. Chua, as you are engaged in lab works, do you still treat patients in the hospital as a urologist?

(2) How long does it take to generate an organoid and also the maintenance too?

(3) How thick is an organoid formed from under the surface of culture? In drug testing, how do you ensure drugs given are exposed to all organoids at different layers of thickness? 

 (4) Could you please share your experience on organoid culture for first-timer? 

Prof. Cheong Soon Keng

(1) Is there a plan or proposal to set up a stem cell depository at UTAR Hospital?

(2) Current status of stem cell therapy under clinical trials in Malaysia. 

Dr. Teoh Hoon Koon

(1) I would like to know your opinion on MSC differentiated from iPSCs. Can these MSCs-iPSCs replace the actual MSCs in clinical therapy? 

(2) Since MSC has limitation as there are possibilities of pro-tumour activity, would you mind to share on how to ensure the MSC treatment will not trigger this? 

(3) I am wondering, have you guys thought of using MSC to co-culture with cancer to assess whether 1. If the cancer would promote the differentiation of MSC into cancer associated fibroblast or 2. If they could suppress the growth of the cancer cells?

Dr. Erica Choong

(1) Have you tried to generate a specific type of cancer from iPSC? 

(2) Do you think the loss of tumorigenicity of cancer upon reprogrammed into iPSC is something to do with the switching of tumor cells back into more "normal state"? 

(3) Could these "iPSCs" remove the tumor cells in the tumor microenvironment?

(4) Since you are generating cancer-derived iPSC, what do you think of cancer-derived iPSC potential in research or in clinical study?

Dr. Wong Chee Yin

(1) For the use of MSC to treat various pathological conditions, once the patients show an improvement, would you guys continue injecting MSC to the patients to further improve the condition? When you stop treating the patients, would the pathological condition appear again?

(2) Can you share how you scale up the MSC numbers for clinical usage? As we know, MSC can be hampered by their limited proliferative rate.

Ms. Tai LiHui

(1) What would be the major advantage of using iPSC compared to MSC?

(2) In your opinion, how much can the MSC-iPSC can differ from the actual MSC? In terms of morphology and the expressions?